2238 Dicker, Adam P. - Thomas Jefferson University - Thomas Jefferson University
axd121

Adam P. Dicker, MD, PhD, FASTRO

Contact Dr. Dicker

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6700
(215) 503-0013 fax

Most Recent Peer-reviewed Publications

  1. Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
  2. A tissue biomarker -based model that identi fies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02
  3. Adjuvant radiation for node-positive disease after prostatectomy: More good news, but who will listen?
  4. Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound
  5. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  6. AAPM and GEC-ESTRO guidelines for image-guided robotic brachytherapy: Report of Task Group 192
  7. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?
  8. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  9. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905
  10. High dose rate brachytherapy boost for prostate cancer: A systematic review
  11. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
  12. A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect
  13. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer
  14. Vorinostat as a radiosensitizer for brain metastasis: A phase i clinical trial
  15. The quality frontier
  16. Minimizing morbidity in radiation oncology: A special issue from future oncology
  17. High-priority topics for cancer quality measure development: Results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit
  18. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?
  19. Study of unrecovered strain and critical stresses in one-way shape memory Nitinol
  20. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
0